268 related articles for article (PubMed ID: 15200426)
21. Drug transporters of platinum-based anticancer agents and their clinical significance.
Burger H; Loos WJ; Eechoute K; Verweij J; Mathijssen RH; Wiemer EA
Drug Resist Updat; 2011 Feb; 14(1):22-34. PubMed ID: 21251871
[TBL] [Abstract][Full Text] [Related]
22. In vitro effects of platinum compounds on renal cellular respiration in mice.
Almarzooqi SS; Alfazari AS; Abdul-Kader HM; Saraswathiamma D; Albawardi AS; Souid AK
Int J Clin Exp Pathol; 2015; 8(1):81-95. PubMed ID: 25755695
[TBL] [Abstract][Full Text] [Related]
23. Differential nephrotoxicity of cisplatin and a novel series of traditional Chinese medicine-platinum anticancer agents correlates with their chemical reactivity towards sulfur-containing nucleophiles.
To KK; Au-Yeung SC; Ho YP
Anticancer Drugs; 2006 Jul; 17(6):673-83. PubMed ID: 16917213
[TBL] [Abstract][Full Text] [Related]
24. Organic cation transporter OCT6 mediates cisplatin uptake and resistance to cisplatin in lung cancer.
Kunii E; Oguri T; Kasai D; Ozasa H; Uemura T; Takakuwa O; Ohkubo H; Takemura M; Maeno K; Niimi A
Cancer Chemother Pharmacol; 2015 May; 75(5):985-91. PubMed ID: 25772757
[TBL] [Abstract][Full Text] [Related]
25. Urinary excretion of carnitine as a marker of proximal tubular damage associated with platin-based antineoplastic drugs.
Haschke M; Vitins T; Lüde S; Todesco L; Novakova K; Herrmann R; Krähenbühl S
Nephrol Dial Transplant; 2010 Feb; 25(2):426-33. PubMed ID: 19736245
[TBL] [Abstract][Full Text] [Related]
26. Structure-toxicity relationships for different types of dinuclear platinum complexes.
Kalayda GV; Fakih S; Bertram H; Ludwig T; Oberleithner H; Krebs B; Reedijk J
J Inorg Biochem; 2006 Aug; 100(8):1332-8. PubMed ID: 16684566
[TBL] [Abstract][Full Text] [Related]
27. Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions.
Ciarimboli G; Deuster D; Knief A; Sperling M; Holtkamp M; Edemir B; Pavenstädt H; Lanvers-Kaminsky C; am Zehnhoff-Dinnesen A; Schinkel AH; Koepsell H; Jürgens H; Schlatter E
Am J Pathol; 2010 Mar; 176(3):1169-80. PubMed ID: 20110413
[TBL] [Abstract][Full Text] [Related]
28. Carrier-mediated uptake of cisplatin by the OK renal epithelial cell line.
Endo T; Kimura O; Sakata M
Toxicology; 2000 May; 146(2-3):187-95. PubMed ID: 10814851
[TBL] [Abstract][Full Text] [Related]
29. PPAR-α Deletion Attenuates Cisplatin Nephrotoxicity by Modulating Renal Organic Transporters MATE-1 and OCT-2.
Freitas-Lima LC; Budu A; Arruda AC; Perilhão MS; Barrera-Chimal J; Araujo RC; Estrela GR
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33049997
[TBL] [Abstract][Full Text] [Related]
30. The copper transporter Ctr1 contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity.
Pabla N; Murphy RF; Liu K; Dong Z
Am J Physiol Renal Physiol; 2009 Mar; 296(3):F505-11. PubMed ID: 19144690
[TBL] [Abstract][Full Text] [Related]
31. [Pharmacokinetic properties of platinium derivatives].
Boisdron-Celle M; Lebouil A; Allain P; Gamelin E
Bull Cancer; 2001 Aug; 88 Spec No():S14-9. PubMed ID: 11567909
[TBL] [Abstract][Full Text] [Related]
32. [Pharmacological approach to the platinum compounds].
Sasaki Y
Gan To Kagaku Ryoho; 1992 Apr; 19(4):456-62. PubMed ID: 1313667
[TBL] [Abstract][Full Text] [Related]
33. Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin.
Cornelison TL; Reed E
Gynecol Oncol; 1993 Aug; 50(2):147-58. PubMed ID: 8375728
[TBL] [Abstract][Full Text] [Related]
34. Antitumor activity, induction of cross-resistance, and nephrotoxicity of a new platinum analogue, cis-1,1-diaminomethylcyclohexaneplatinum(II) sulfate, and of cis-diamminedichloroplatinum(II) in an immunocytoma model in the LOU/M rat.
de Jong WH; Steerenberg PA; Vos JG; Bulten EJ; Verbeek F; Kruizinga W; Ruitenberg EJ
Cancer Res; 1983 Oct; 43(10):4927-34. PubMed ID: 6683993
[TBL] [Abstract][Full Text] [Related]
35. Antitumor activity and nephrotoxicity of a novel platinum complex, [1,3-bis(diphenylphosphino)propane](trans-1-dach)platinum(I I) dinitrate.
Baek MS; Rho YS; Jung JC; Chang SG; Nomura M; Miyamoto KJ
Anticancer Res; 1997; 17(2A):955-9. PubMed ID: 9137434
[TBL] [Abstract][Full Text] [Related]
36. Use of a toxicity factor to explain differences in nephrotoxicity and myelosuppression among the platinum antitumour derivatives cisplatin, carboplatin and nedaplatin in rats.
Hanada K; Asano K; Nishimura T; Chimata T; Matsuo Y; Tsuchiya M; Ogata H
J Pharm Pharmacol; 2008 Mar; 60(3):317-22. PubMed ID: 18284811
[TBL] [Abstract][Full Text] [Related]
37. Functional cooperation of URAT1 (SLC22A12) and URATv1 (SLC2A9) in renal reabsorption of urate.
Nakanishi T; Ohya K; Shimada S; Anzai N; Tamai I
Nephrol Dial Transplant; 2013 Mar; 28(3):603-11. PubMed ID: 23291366
[TBL] [Abstract][Full Text] [Related]
38. New clues for nephrotoxicity induced by ifosfamide: preferential renal uptake via the human organic cation transporter 2.
Ciarimboli G; Holle SK; Vollenbröcker B; Hagos Y; Reuter S; Burckhardt G; Bierer S; Herrmann E; Pavenstädt H; Rossi R; Kleta R; Schlatter E
Mol Pharm; 2011 Feb; 8(1):270-9. PubMed ID: 21077648
[TBL] [Abstract][Full Text] [Related]
39. Analysis of cytotoxicities of platinum compounds.
Goodisman J; Hagrman D; Tacka KA; Souid AK
Cancer Chemother Pharmacol; 2006 Jan; 57(2):257-67. PubMed ID: 16028101
[TBL] [Abstract][Full Text] [Related]
40. The interaction of platinum-based drugs with native biologically relevant proteins.
Brauckmann C; Wehe CA; Kieshauer M; Lanvers-Kaminsky C; Sperling M; Karst U
Anal Bioanal Chem; 2013 Feb; 405(6):1855-64. PubMed ID: 23052861
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
